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ABSTRACT 
Objective: To study the occurrence, causes, predisposing factors and management of potassium abnormalities in a tertiary care hospital. 
Methods: Inour study which was for aduration of six months, we recorded patient demographics, electrolyte levels, complete blood picture, liver 
function tests, renal parameters, comorbid conditions, medication reconciliation and electro cardio gram (ECG) changes. The data was analyzed to 
find out the cause for potassium abnormality and was categorize based on their severity. 
Results: A total of 200 cases of potassium abnormalities was normalized during the study period. We observed 158(80%) cases with hypokalemia, 
37 (17%) cases with hyperkalemia and 5 (3%) cases with subsequent Potassium abnormalities. We observed the majority of hypokalemiaare with 
disease induced 87(55.06%) cases and 118 (74.0%) cases were with mild hypokalemia. Syrup potassium chloride was used to normalize the serum 
potassium levels. Majority of the hyperkalemia cases were disease induced and was found in 19(51.35%) cases and 22 (59.45%) cases come under 
mild category which was managed with injection calcium gluconate. 
Conclusion: Hypokalemia was the most common potassium abnormality seen in hospitalized patients. Disease induced potassium abnormalities 
was found to be more common in both hypo and hyperkalemia. The potassium levels were normalized with no major negative outcomes. 
Continuous monitoring of electrolyte levels is required for the patient to prevent further complications. 
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In physiology, the primary ions of the electrolytes are sodium (Na+), 
potassium (K+), calcium (Ca2+), chloride (Cl-), hydrogen phosphate 
(HPO4 2-), and hydrogen carbonate (HCO3-) [1]. Potassium is one 
amongst those which is the most abundant cation in the body, with 
estimated total-body stores of 3,000 to 4,000mmol. About 98% of 
potassium is seen within the intracellular compartment, and the 
remaining 2% is distributed within the extracellular compartment. 
The Sodium-Potassium adenosine triphosphate (Na+-K+-ATPase) 
pump located in the cell membrane is responsible for the 
compartmentalization of Potassium. This pump is an active 
transport system that maintains increased intracellular stores of 
Potassium by transporting Sodium out of the cell and Potassium into 
the cell at a ratio of 3:2. Consequently, the pump maintains a higher 
concentration of potassium inside the cell. Potassium plays a main 
role in the transmission of nerve impulse, contraction of muscles 
and maintenance of fluid balance in the body [2]. 
The normal value of serum potassium is 3.5-5.0 mmol/l. Hypokalemia 
is an electrolyte imbalance and is indicated by a low level of Potassium 
in the blood. Hypokalemia is divided into 3 categories based on serum 
potassium levels; mild 3.0-3.5 mmol/l, moderate 2.5-3.0 mmol/l and 
severe<2.5 mmol/l. Up to 21% of hospitalized patients have serum 
potassium levels lower than 3.5mmol/l, with 5% of patients exhibiting 
potassium levels lower than 3 mmol/l [3].Hyperkalemia is defined as 
serum potassium concentration greater than 5.0mmol/l. It is less 
common than hypokalemia. Hyperkalemia is divided into 3 
categories based on serum electrolytes; mild 5.1-5.5 mmol/l, 
moderate 5.6-6.0 mmol/l and severe>6 mmol/l. The incidence of 
hyperkalemia in hospitalized patients has been estimated to be 1.4-
10% [4]. 
One of the most common electrolyte complications are Potassium 
abnormalities in hospitalized patients. Potassium is one of the 
critical electrolytes involved in various cellular activities. Potassium 
loss in the body affects the quality of life of the patient and increases 
morbidity and mortality. So, it is very important to monitor the 
potassium levels, initiate the standard treatment immediately and 
normalize them [5]. Hence in this study, we aimed to capture the 
data regarding the potassium abnormalities in the hospital setting 
and understand the causes and their management strategies.  
MATERIALS AND METHODS 
The present study was a prospective and observational study conducted 
at Apollo Hospitals, Jubilee Hills, Hyderabad, India. This study was 
approved by the institutional ethical committee (No: SVCP/2015/28). 
Case records of the inpatients who are above or equal to 18 y with 
abnormal potassium values were included and outpatients are excluded 
from the study. The data was collected regarding patient’s demographics 
such as age, family history, co-morbid conditions, abnormal potassium 
values, dose, frequency, lab parameters such as serum electrolytes 
values (Sodium, Calcium, Magnesium and Chlorides), Serum Creatinine 
(S. Cr), complete blood picture, electro cardiogram (ECG), liver function 
tests like albumin, globulin, and alkaline phosphatase were recorded. 
Statistical analysis is done by using descriptive statistics and CI of mean. 
Descriptive analysis was used to report the findings of continuous data 
and Categorical data, potassium abnormalities was analyzed by 
confidence intervals of their respective means. 
RESULTSAND DISCUSSION 
A total of 200 in-patients who have abnormal potassium values were 
considered for the study, of which the majority were males (53%). 
Higher percentage of our study population belonged to the age 
group of 51-60 y (27%), as it is known that risk of cardiovascular 
disease (Hypertension, Coronary artery diseases) and renal disease 
(Chronic kidney disease and Acute kidney injury) are significantly 
higher in this age(table 1). Blood pressure increases with age and 
lifetime risk of developing cardiovascular diseases among those of 
55 y age and older was observed to be 90% [6,7]. 
Majority of our study population were found to be overweight and obese 
with an average body mass index (BMI) of 27.4 kg/m².Obesity is 
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characterized by a marked insulin resistance which involves an 
abnormal regulation of Potassium uptake and metabolism (table 1). 
The disease induced hypokalemia 87 (55.06%) cases and hyperkalemia 
19 (51.35%) cases, and the drug-induced hypokalemia 71 (44.93%) 
cases and hyperkalemia 18 (48.65%) cases, were observed among 158 
cases of hypokalemia (The 95% confidence interval extends from 0.7281 
to 0.8410) and37 cases of hyperkalemia (The 95% confidence interval 
extends from 0.1370 to 0.2449) respectively (table 2). 
Chronic kidney disease (CKD), diabetes mellitus (DM), hypertension 
(HTN), coronary artery disease (CAD) and urinary tract infections 
(UTI) are the conditions where potassium abnormalities were seen 
to a larger extent. In our study we noted that Lactulose,  furosemide, 
methylprednisone, noradrenaline, actrapid, perindopril, enalapril, 
irbesartan, telmisartan, aspirin, and combinational drugs like 
furosemide +lactulose, non-steroidal anti-inflammatory drugs and 
angiotensin-converting enzyme inhibitors (NSAIDS+ACEI),-
blockers, angiotensin receptor blockers and beta blockers(ARB+β 
blockers)are the drugs causing potassium abnormalities (table 3). 
Among disease induced hypokalemia, nephrotic disorders are the 
prime reasons, it can be because of increased water intake and 
increased reabsorption of sodium chloride and water offer to sustain 
the edemas, while aldosterone promotes renal excretion of K+ and 
H+ leads to develop hypokalemia and alkalosis [8, 9]. 
 
Table 1: Patient demographics (N=200) 
Gender No of cases (%) 
Females 94 (47%) 
Males 106 (53%) 
Age 
Years No of cases (%) 
18-30  19 (9.5%) 
31-40 27 (13.5%) 
41-50 27 (13.5%) 
51-60 54 (27%) 
61-70 45 (22.5%) 
>71 28 (14%) 
BMI 
BMI (kg/m²) Range No of cases (%) 
Underweight<18 40 (20%) 
Normal 18.5-24.9 46 (23%) 
Overweight 25-29.9 70 (35%) 
Obese 30-39.9 34 (17%) 
Morbid obese>40 10 (5%) 
 
Table 2: Details of Potassium abnormalities in the study population (N=200) 
Potassium abnormality Hypokalemia Hyperkalemia Subsequent K+ abnormality 
Serum K⁺ value<3.5 mmol/l 158* (80%) - 05(3%) 
>5.0 mmol/l -  37 **(17%) - 
Severity 
Mild 118 (74.6%) 22 (59.45%) 03 (60%) 
Moderate 35 (22.15%) 10 (27.02%) 0 
Severe 05 (3.16%) 05 (13.51%) 02 (40%) 
Etiology 
Categories Hypokalemia Hyperkalemia Subsequent potassium abnormality 
Disease induced 87 (55.06%) 19 (51.35%) 05 (100%) 
Drug induced 71 (44.93%) 18 (48.65%) - 
ECG Changes (n= 17) 
Sinus Tachycardia Drug-induced Disease induced 
Hypokalemia 10 (71%) 4 (29%) 
Hyperkalemia 1 (33.3%) 2 (66.7%) 
*95%CI 0.7281 to 0.8410**95% CI 0.1370 to 0.2449 
 
Table 3: Common drugs in dosing potassium abnormalities (N = 200) 
Drugs causing potassium abnormalities 
Class Drug No of cases (%) 
Hypokalemia (n = 158) 
Laxatives Lactulose 19 (26.76%) 
Loop diuretics Furosemide 13 (18.30%) 
Corticosteroids Methyl prednisone 06 (8.45%) 
Catecholamine Nor adrenaline 01 (1.40%) 
Insulin Actrapid 01 (1.40%) 

















ACEI’s: Angiotensin Converting Enzyme Inhibitors, ARB’s: Angiotensin Receptor Blockers, NSAIDS: Non-Steroidal Anti-Inflammatory Drugs 
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Management of Hypokalemia and Hyperkalemia:  
The Serum Potassium levels in hypokalemia patients were 
normalized with 10ml (13.3mEq) of Potassium chloride syrup, 
which was administered three times a day in 27 (17 %) cases, which 
showed 0.5mmol/l increase in Serum Potassium. Injection 
potassium chloride (KCl) was given in 28 (17.7%) cases and were 
managed with 40mEq given twice a day, which showed an increase 
of 0.3mmol/l serum potassium(table 4). 
Potassium citrate and magnesium citrate (Potrate M) was also given for 
the management of hypokalemia when there was an abnormality of 
magnesium in metabolic alkalosis patients. Potrate M was given in 
4(2.5%) cases with 15 ml twice a day, showed an increase of 0.5mmol/l 
serum potassium. In our study, combination therapy was given for the 
management of hypokalemia. Syrup potassium chloride (Potrate) 20ml 
and injection Potassium chloride 10 mEq, stat was given in 8 (5%) cases, 
which showed an increase of 0.4 mmol/l (table 4). 
For the management of hyperkalemia, parenteral, nebulizers and 
oral dosage forms were prescribed. Calcium gluconate, insulin, 
potassium bind was given as injections and as nebulizers  
salbutamol +ipratropium Bromide, Salbutamol were given and as 
oral dosage form furosemide, Potassium bind sachet, Sodium 
bicarbonate were given. Out of all these drugs in our studyinj. 
Calcium gluconate, 10ml stat was found to decrease serum 
potassium by 0.2mmol/l in 3 (8.1%) cases and Potassium bind 
sachet 15ml per oral once a day, salbutamol+ ipratropium 
Bromide2cc nebulizer four times a day and Salbutamol 1 cc 
nebulizer three times a day were given in2 (5.4%), 2(5.4%), 1(2.7%) 
cases respectively which showed decrease of 0.1 mmol/l serum 
potassium in all the three. Sodium bicarbonate 500mg per oral twice 
daily was given in 2 (5.4%) cases which showed a decrease of 1.1 
mmol/l of serum Potassium.Furosemide20mg per oral twice daily 
and subcutaneous Insulin 16 units once a day was given in 1(2.7%) 
case which showed decrease of 0.2mmol/l serum potassium 
respectively(table 4). 
Hyperkalemia was also managed using more than one drug. In our 
study the combination drugs were inj. Calcium gluconate 10 ml stat 
and Salbutamol 2cc nebulizer three times a day was given in 2 
(5.4%) cases Which Showed a decrease of 0.3mmol/l of serum 
potassium(table 4). 
 
Table 4: Management of potassium abnormalities in the study population (N=200) 
Hypokalemia (n=158) 
Drug Dose No of 
cases 
Route Frequency Average increase in 
K+ value (mmol) 
Syrup  
Potassium chloride 












Inj. Potassium chloride  40meq 28 IV BD  28 0.3 






Potassium citrate and Magnesium citrate 
+ 







Drug Dose No of 
cases 
Route Frequency Average decrease in 
K+value (mmol) 
Calcium gluconate 10 ml 03 IV Stat 0.2 
Furosemide 20 mg 01 PO BD 0.2 
Potassium Bind Sachet 15 ml 02 PO OD 0.1 
Salbutamol +Ipratropium Bromide 2cc 02 Neb QID 0.1 
Salbutamol 1cc 01 Neb QID 0.1 
Sodium bicarbonate 500 mg 02 PO BD 1.1 











In a few cases extra supplementation of potassium led to 
hyperkalemia and upon treatment, it subsequently resulted in 
hypokalemia. Such kind of Potassium abnormalities was found to be 
5(3%) cases in our study. In subsequent hypokalemia and 
hyperkalemia, mild and severe cases were seen in 3 and 2 cases 
respectively, which are found in both disease and drug induced 
Potassium abnormalities (table 2). 
Patients with longer duration of hospital stay were observed to be with 
subsequent hypokalemia and hyperkalemia as these patients require 
continuous monitoring. The initiation of potassium supplements was 
influenced by the duration of stay in these patients. Naranjo’s causality 
scale was used to assess the causality of potassium abnormalities. In our 
study, we found that about half of the cases of druginduced hypokalemia 
and the drug-induced hyperkalemia were possible (table 5). 
 
Table 5: Causality assessment 
 Naranjo’s scale (n=89) Hypokalemia (71) Hyperkalemia (18) 
Probable (5-8) 25 06 
Possible(1-4) 30 09 
Definite(≥9) 14 03 
Doubtful 02 00 
 
LIMITATIONS 
Difficulty in accessing data in ICU and Hemodialysis department. 
Since, data collected was from inpatient only, the status of 
improvement in potassium levels after discharge was unavailable.  
CONCLUSION 
From our study, we observed that hypokalemia was the most 
common potassium abnormality. The common causes of the 
abnormalities were because of diseases. However, they were mild in 
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nature and were treated with no negative outcome. Regular 
monitoring is required to prevent further complications and to 
improve the quality of life. 
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